弥漫性硬化型甲状腺乳头状癌的分子遗传学
该研究对22例弥漫性硬化型甲状腺乳头状癌(DSPTC)患者的石蜡包埋组织进行Sanger测序和NGS基因面板检测,发现融合基因常见(CCDC6-RET、NCOA4-RET、STRN-ALK),BRAFV600E罕见,RAS、PTEN、PIK3CA、TERT启动子突变均未发现;约三分之二病例存在POLE、NF1、CDKN2A、BRCA2、TP53、SETD2、ATM、FLT3、ROS1的可能致病性变异,未观察到明确的基因型/表型相关性。
要点
- DSPTC中融合基因常见:19例中CCDC6-RET 5例、NCOA4-RET 1例、STRN-ALK 1例。
- BRAFV600E罕见:19例中仅2例(10.5%);RAS、PTEN、PIK3CA、TERT启动子突变均未发现。
- 19例中13例(68.4%)存在POLE、NF1、CDKN2A、BRCA2、TP53、SETD2、ATM、FLT3、ROS1的可能致病性变异。
核心结论
- 在DSPTC中,融合基因常见,BRAFV600E罕见,其他常见点突变缺失;POLE、NF1、CDKN2A、BRCA2、TP53、SETD2、ATM、FLT3和ROS1的致病性或可能致病性变异发生于约三分之二的DTPTC病例。
研究设计与样本
- 从22例DSPTC患者(15例女性,7例男性,中位年龄18岁,范围8-81岁)的石蜡块中提取DNA;采用基于聚合酶链反应的Sanger测序和下一代测序(NGS)基因面板刻画肿瘤基因组图谱,并将遗传改变分类为明确致病性或可能致病性。
主要发现
- 3例仅行Sanger测序,BRAFV600E、HRAS、KRAS、NRAS、TERT启动子、PTEN和PIK3CA突变均为阴性。
- 19例NGS检测中,10例(52.6%)存在明确致病性改变:BRAFV600E 2/19(10.5%)、CCDC6-RET(RET/PTC1)5/19(26.3%)、NCOA4-RET(RET/PTC3)1/19(5.3%)、STRN-ALK融合1/19(5.3%)、TP53突变2/19(10.6%)。
- 19例中13例(68.4%)存在可能致病性改变,包括POLE(31.6%)、CDKN2A(26%)、NF1(21%)、BRCA2(15.8%)、SETD2(5.3%)、ATM(5.3%)、FLT3(5.3%)、ROS1(5.3%)变异。
- 1例患者基因面板未显示任何改变;所有患者均未发现RAS、PTEN、PIK3CA或TERT启动子突变。
- 未观察到明确的基因型/表型相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Diffuse sclerosing papillary thyroid cancer (DSPTC) is rare, with limited data on its molecular genetics. OBJECTIVE: We studied the molecular genetics of a cohort of DSPTC. METHODS: DNA was isolated from paraffin blocks of 22 patients with DSPTC (15 females, 7 males, median age 18 years, range 8-81). We performed polymerase chain reaction-based Sanger sequencing and a next-generation sequencing (NGS) gene panel to characterize the genomic landscape of these tumors. We classified genetic alterations to definitely or probably pathogenic. Definitely pathogenic are genetic alterations that are well known to be associated with PTC (e.g., BRAFV600E). Probably pathogenic are other alterations in genes that were reported in The Cancer Genome Atlas or the poorly differentiated and anaplastic thyroid cancer datasets. RESULTS: Three tumors were tested only by Sanger sequencing and were negative for BRAFV600E, HRAS, KRAS, NRAS, TERT promoter, PTEN, and PIK3CA mutations. The other 19 tumors tested by NGS showed definitely pathogenic alterations in 10 patients (52.6%): 2/19 (10.5%) BRAFV600E, 5/19 (26.3%) CCDC6-RET (RET/PTC1), 1/19 (5.3%) NCOA4-RET (RET/PTC3), 1/19 (5.3%) STRN-ALK fusion, and 2/19 (10.6%) TP53 mutations. Probably pathogenic alterations occurred in 13/19 tumors (68.4%) and included variants in POLE (31.6%), CDKN2A (26%), NF1 (21%), BRCA2 (15.8%), SETD2 (5.3%), ATM (5.3%), FLT3 (5.3%), and ROS1 (5.3%). In 1 patient, the gene panel showed no alterations. No mutations were found in the RAS, PTEN, PIK3CA, or TERT promoter in all patients. There was no clear genotype/phenotype correlation. CONCLUSION: In DSPTC, fusion genes are common, BRAFV600E is rare, and other usual point mutations are absent. Pathogenic and likely pathogenic variants in POLE, NF1, CDKN2A, BRCA2, TP53, SETD2, ATM, FLT3, and ROS1 occur in about two-thirds of DTPTC.
引用
- Alswailem M, Alghamdi B, Alotaibi A, et al. Molecular Genetics of Diffuse Sclerosing Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2023. PMID: 36995892. doi:10.1210/clinem/dgad185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。